Hamzah Adwan

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 7

Top Topics

Combination Therapy

Cross Sectional

Diffusion Weighted

Radiofrequency Ablation

Top Venues

Journal of personalized medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Joseph Vogl, John Bielfeldt, Ulrich Kübler, Hamzah Adwan
CT-Guided Percutaneous Cryoablation of Breast Cancer: A Single-Center Experience. Cancers 16 (13) (2024)
Thomas Joseph Vogl, John Bielfeldt, Ulrich Kübler, Hamzah Adwan
CT-Guided Percutaneous Cryoablation of Breast Cancer: A Single-Center Experience. Cancers 16 (13) (2024)
Thomas Joseph Vogl, Hamzah Adwan, Leonard Wolff, Maximilian Lahrsow, Tatjana Gruber-Rouh, Nour-Eldin Abdelrehim Nour-Eldin, Jörg Trojan, Wolf Otto Bechstein, Nagy N N Naguib
Retrospective Long-Term Evaluation of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma over 20 Years. Cancers 16 (8) (2024)
Thomas Joseph Vogl, Hamzah Adwan, Leonard Wolff, Maximilian Lahrsow, Tatjana Gruber-Rouh, Nour-Eldin Abdelrehim Nour-Eldin, Jörg Trojan, Wolf Otto Bechstein, Nagy N N Naguib
Retrospective Long-Term Evaluation of Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma over 20 Years. Cancers 16 (8) (2024)
Thomas Joseph Vogl, Michael Bialek, Katrin Eichler, Renate Hammerstingl, John Bielfeldt, Stephan Zangos, Jan-Erik Scholtz, Hamzah Adwan
Short- and Long-Term Outcomes after Radiofrequency Ablation of Osteoid Osteomas. Journal of personalized medicine 14 (4) (2024)
Thomas Joseph Vogl, Michael Bialek, Katrin Eichler, Renate Hammerstingl, John Bielfeldt, Stephan Zangos, Jan-Erik Scholtz, Hamzah Adwan
Short- and Long-Term Outcomes after Radiofrequency Ablation of Osteoid Osteomas. Journal of personalized medicine 14 (4) (2024)
Hamzah Adwan, Moath Adwan, Thomas Joseph Vogl
Combination Therapy of Bland Transarterial Embolization and Microwave Ablation for Hepatocellular Carcinoma within the Milan Criteria Leads to Significantly Higher Overall Survival. Cancers 15 (20) (2023)